| Literature DB >> 30506689 |
Elisa Danese1, Sara Raimondi2, Martina Montagnana1, Angela Tagetti2, Taimour Langaee3, Paola Borgiani4, Cinzia Ciccacci4, Antonio J Carcas5,6, Alberto M Borobia5,6, Hoi Y Tong5,6, Cristina Dávila-Fajardo7, Mariana Rodrigues Botton8, Stephane Bourgeois9, Panos Deloukas9,10, Michael D Caldwell11, Jim K Burmester12, Richard L Berg13, Larisa H Cavallari3, Katarzyna Drozda14, Min Huang15, Li-Zi Zhao15, Han-Jing Cen16, Rocio Gonzalez-Conejero17, Vanessa Roldan17, Yusuke Nakamura18, Taisei Mushiroda18, Inna Y Gong19, Richard B Kim19, Keita Hirai20, Kunihiko Itoh20, Carlos Isaza21, Leonardo Beltrán21,22, Enrique Jiménez-Varo23, Marisa Cañadas-Garre24, Alice Giontella2, Marianne K Kringen25,26, Kari Bente Foss Haug27, Hye Sun Gwak28, Kyung Eun Lee29, Pietro Minuz2, Ming Ta Michael Lee30,31, Steven A Lubitz32, Stuart Scott33, Cristina Mazzaccara34,35, Lucia Sacchetti34,35, Ece Genç36, Mahmut Özer36, Anil Pathare37, Rajagopal Krishnamoorthy38, Andras Paldi39, Virginie Siguret40,41, Marie-Anne Loriot42,43, Vijay Kumar Kutala44, Guilherme Suarez-Kurtz45, Jamila Perini46, Josh C Denny47, Andrea H Ramirez48, Balraj Mittal49, Saurabh Singh Rathore49, Hersh Sagreiya50, Russ Altman50, Mohamed Hossam A Shahin3, Sherief I Khalifa51, Nita A Limdi52, Charles Rivers52, Aditi Shendre53, Chrisly Dillon52, Ivet M Suriapranata54, Hong-Hao Zhou55, Sheng-Lan Tan56, Vacis Tatarunas57, Vaiva Lesauskaite57, Yumao Zhang58, Anke H Maitland-van der Zee58,59, Talitha I Verhoef60, Anthonius de Boer58, Monica Taljaard61, Carlo Federico Zambon62, Vittorio Pengo63, Jieying Eunice Zhang64, Munir Pirmohamed64, Julie A Johnson3, Cristiano Fava2.
Abstract
The cytochrome P450 (CYP)4F2 gene is known to influence mean coumarin dose. The aim of the present study was to undertake a meta-analysis at the individual patients level to capture the possible effect of ethnicity, gene-gene interaction, or other drugs on the association and to verify if inclusion of CYP4F2*3 variant into dosing algorithms improves the prediction of mean coumarin dose. We asked the authors of our previous meta-analysis (30 articles) and of 38 new articles retrieved by a systematic review to send us individual patients' data. The final collection consists of 15,754 patients split into a derivation and validation cohort. The CYP4F2*3 polymorphism was consistently associated with an increase in mean coumarin dose (+9% (95% confidence interval (CI) 7-10%), with a higher effect in women, in patients taking acenocoumarol, and in white patients. The inclusion of the CYP4F2*3 in dosing algorithms slightly improved the prediction of stable coumarin dose. New pharmacogenetic equations potentially useful for clinical practice were derived.Entities:
Mesh：
Substances：
Year: 2019 PMID： 30506689 PMCID： PMC6542461 DOI： 10.1002/cpt.1323
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875